Connect with us

Health

Nearly 3 million People Access Hepatitis C Cure—WHO

Published

on

By Dipo Olowookere

The World Health Organisation (WHO) has revealed that a record 3 million people were able to obtain treatment for hepatitis C over the past two years, and 2.8 million more people embarked on lifelong treatment for hepatitis B in 2016.

This information is coming as stakeholders in the health sector across the globe gather in Brazil for the World Hepatitis Summit.

WHO stated that lately, there has been increasing global momentum in the response to viral hepatitis.

“We have seen a nearly 5-fold increase in the number of countries developing national plans to eliminate life-threatening viral hepatitis over the last 5 years,” says Dr Gottfried Hirnschall, Director of WHO’s Department of HIV and Global Hepatitis Programme. “These results bring hope that the elimination of hepatitis can and will become a reality.”

Hosted by the Government of Brazil, the World Hepatitis Summit 2017 is being co-organized by the World Health Organization and the World Hepatitis Alliance. The Summit aims to encourage more countries to take decisive action to tackle hepatitis, which still causes more than 1.3 million deaths every year and affects more than 325 million people.

“We cannot lose sight of the fact that last year 194 governments committed to eliminating viral hepatitis by 2030. For sure we are still a long way from this goal but that doesn’t mean it’s some unattainable dream. It’s eminently achievable. It just requires immediate action,” says Charles Gore, President of World Hepatitis Alliance. “The World Hepatitis Summit 2017 is all about how to turn WHO’s global strategy into concrete actions and inspire people to leave with a ‘can do’ attitude.”

“Brazil is honoured to host the World Hepatitis Summit 2017 – and welcomes this extraordinary team of experts, researchers, managers and civil society representatives to discuss the global health problem posed by viral hepatitis,” says Dr Adele Schwartz Benzaken, Director of the Brazilian Ministry of Health’s Department of Surveillance, Prevention and Control of STIs, HIV/AIDS and Viral Hepatitis.” Brazil is committed to taking recent advances in its response to hepatitis forward – on the road to elimination.”

Progress in treatment and cure

Many countries are demonstrating strong political leadership, facilitating dramatic price reductions in hepatitis medicines, including through the use of generic medicines—which allow better access for more people within a short time.

In 2016, 1.76 million people were newly treated for hepatitis C, a significant increase on the 1.1 million people who were treated in 2015. The 2.8 million additional people starting lifelong treatment for hepatitis B in 2016 was a marked increase from the 1.7 million people starting it in 2015. But these milestones represent only initial steps – access to treatment must be increased globally if the 80% treatment target is to be reached by 2030.

However, funding remains a major constraint: most countries lack adequate financial resources to fund key hepatitis services.

Diagnosis challenge

To achieve rapid scale-up of treatment, countries need urgently to increase uptake of testing and diagnosis for hepatitis B and C. As of 2015, an estimated 1 in 10 people living with hepatitis B, and 1 in 5 people living with hepatitis C, were aware of their infection. Countries need to improve policies, and programmes to increase awareness and subsequent diagnosis.

Prevention gaps

Countries need to provide a full range of hepatitis prevention services that are accessible to different population groups, particularly those at greater risk.

Largely due to increases in the uptake of hepatitis B vaccine, hepatitis B infection rates in children under 5 fell to 1.3% in 2015, from 4.7% in the pre-vaccine era.

However, the delivery of other prevention services, such as birth-dose vaccination for hepatitis B, harm reduction services for people who inject drugs, and infection control in many health services, remains low. This has led to continuing rates of new infections, including 1.75 million new hepatitis C cases every year.

Need for innovation

Innovation in many aspects of the hepatitis response must continue. New tools required include a functional cure for hepatitis B infection and the development of more effective point-of-care diagnostic tools for both hepatitis B and C.

“We cannot meet the ambitious hepatitis elimination targets without innovation in prevention interventions and approaches, and implementing them to scale,” said Dr Ren Minghui, Assistant Director-General for Communicable Diseases, WHO. “The great successes of hepatitis B vaccination programmes in many countries need to be replicated and sustained globally in the context of moving forward to universal health coverage.“

Implementation of elimination strategy

The World Hepatitis Summit 2017 will be attended by over 900 delegates from more than 100 countries, including Ministers of Health, national programme managers, and representatives from organizations of people affected by viral hepatitis. The Summit will review progress and renew commitments by global partners to achieve the elimination of viral hepatitis by 2030 – a target reflected in WHO’s elimination strategy and the UN Sustainable Development Goals.

Dipo Olowookere is a journalist based in Nigeria that has passion for reporting business news stories. At his leisure time, he watches football and supports 3SC of Ibadan. Mr Olowookere can be reached via [email protected]

Advertisement
1 Comment

1 Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

Chimamanda: MDCN Suspends Euracare Medical Director, Anesthesiologist

Published

on

Euracare

By Adedapo Adesanya

The Medical and Dental Practitioners Investigation Panel of the Medical and Dental Council of Nigeria (MDCN) has invoked its order of suspension against the Medical Director of Euracare Multi-Specialist Hospital, Dr Tosin Majekodunmi, and two others, after establishing a prima facie case of medical negligence against them in the management of the late Nkanu Adichie-Esege.

Nkanu, the son of renowned Nigerian author, Chimamanda Ngozi Adichie and Dr Ivara Esege, died on January 7, 2026, after receiving care at Atlantis Hospital and undergoing medical procedures at Euracare Multi-Specialist Hospital in Lagos. He was 21 months old.

Apart from the Medical Director at Euracare, the panel also suspended the anesthesiologist at the same hospital, Dr Titus Ogundare, as well as the Chief Medical Officer at Atlantis Pediatric Hospital, Dr Atinuke Uwajeh.

The trio were suspended from medical practice in Nigeria pending the determination of their case by the Medical and Dental Practitioners Disciplinary Tribunal.

A statement signed by the committee’s secretary, Dr Enejo Abdu, also disclosed it was determining if there is a prima facie case of professional misconduct against 10 other doctors.

These are Dr Adeseye Akinsete, Dr Chidinma Ohagwu, Dr Anthony Ajeh, Dr Amarachi Bayo, and Dr Nkechi Peji. Others are Dr Olaoye Oludare, Dr Agaja Oyinkansola, Dr Patricia Akintan, Dr Babatunde Bamgboye, and Dr Raji Faidat.

The panel, which also cleared eight other doctors, reached these decisions after considering the complaint against all 21 doctors and reviewing their counter-affidavits, including their oral depositions on oath.

It concluded its investigation at its 25th session held at Excel Hotel & Resort in Abuja on February 17 and 18, 2026.

The 21-month-old child, Nkanu Adichie-Esege, was initially admitted to Atlantis Hospital in Lagos for what was described as a worsening but initially mild illness.

While arrangements were being made to transfer him to Johns Hopkins Hospital in the United States, Atlantis referred him to Euracare for pre-flight diagnostic procedures, including an MRI, lumbar puncture, and insertion of a central line.

However, the child passed following the procedures.

His parents have alleged medical negligence and professional misconduct in connection with his death.

In a legal notice dated January 10, 2026, issued by the law firm led by Kemi Pinheiro (SAN), Ms Adichie and her husband accused Euracare, its anesthesiologist, and other attending medical personnel of breaching the duty of care owed to their son.

The notice stated that the child, born on March 25, 2024, was referred to Euracare on January 6, 2026, for diagnostic and preparatory procedures ahead of an emergency medical evacuation to the United States, where a specialist team was reportedly on standby.

The procedures reportedly included: Echocardiogram, Brain MRI, and insertion of a peripherally inserted central catheter.

Lumbar puncture, Intravenous sedation using propofol was administered.

The parents alleged that the child developed sudden and severe complications while being transported to the cardiac catheterisation laboratory after the MRI.

The development has raised worries and questions about the country’s healthcare.

Continue Reading

Health

Nigeria to Receive Breakthrough HIV Prevention Drug Lenacapavir—NACA

Published

on

Lenacapavir

By Adedapo Adesanya

The National Agency for the Control of AIDS (NACA) has announced that Nigeria would take delivery of Lenacapavir, a groundbreaking human immunodeficiency virus (HIV) prevention drug that has shown 100 per cent effectiveness in preventing the viral infection in clinical trials.

A short statement released by the Head of Public Relations for NACA, Mrs Toyin Aderibigbe, on Monday said the agency had secured regulatory approval from the National Agency for Food and Drug Administration and Control (NAFDAC).

HIV over time causes acquired immunodeficiency syndrome (AIDs), a condition in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive.

Lenacapavir is an injectable treatment administered twice a year, making it a more convenient alternative to daily oral prevention drugs.

The drug is expected to be available in Nigeria and 119 other low- and middle-income countries at an affordable price of $40 per person annually, thanks to voluntary licensing agreements with generic manufacturers.

“The Government of Nigeria is advancing preparations for the introduction and rollout of Lenacapavir as Pre-Exposure Prophylaxis (PrEP).

“This is part of the government’s commitment to strengthen HIV prevention and accelerate progress toward epidemic control,” the statement read.

NACA listed some significant milestones achieved, including completion of landscape and readiness assessments across ten states: Akwa Ibom, Anambra, Benue, Cross River, Ebonyi, FCT, Gombe, Kano, Kwara, and Lagos, alongside regulatory approval by NAFDAC.

“The commodities are expected in the country in March 2026,” NACA noted.

Nigeria has approximately 1.9 million people living with HIV, with a national prevalence of 1.3% among adults aged 15-49 years.

The country recorded 74,000 new HIV infections and 51,000 AIDS-related deaths in 2021.

The South-South zone has the highest HIV prevalence at 3.1%, while women aged 15-49 years are more than twice as likely to be living with HIV as men.

Daily oral PrEP has been available in Nigeria since 2016, but uptake varies. Adherence issues like pill fatigue, stigma, limited awareness, and inconsistent access have hindered wider use.

Newer PrEP options include injections that last two or six months, providing an alternative for those who prefer less frequent dosing and may overcome many barriers of daily oral use.

Continue Reading

Health

Union Disrupts NAFDAC Operations in Lagos Over Sachet Alcohol Ban

Published

on

disrupt nafdac office lagos

By Adedapo Adesanya

Members of the National Union of Food, Beverage and Tobacco Employees protested at the Lagos office of the National Agency for Food and Drug Administration and Control (NAFDAC), disrupting operations in reaction to the ban on sachet alcohol.

The protesting union members barricaded the agency’s premises in Isolo, meaning staff who arrived early to resume duty were forced to remain outside the complex.

Recall that NAFDAC has continued the ban on alcoholic beverages sold in sachets and PET bottles below 200 millilitres, despite calls from certain quarters, including the picketers.

The union is demanding the immediate unsealing of affected factories and production lines, warning that sustained enforcement of the policy could trigger significant economic consequences across the industry.

It is the second time this month that union members disrupted the Lagos NAFDAC office over what they described as the agency’s refusal to comply with an alleged federal government directive to suspend enforcement of the ban on the production and sale of alcoholic beverages in sachets.

The union claimed that directives had been issued by the Office of the Secretary to the Government of the Federation and the Office of the National Security Adviser, calling for the suspension of enforcement and the reopening of sealed production lines.

However, NAFDAC dismissed the claims, maintaining that it had not received any official instruction from the Federal Government to halt enforcement of the ban on sachet and PET-bottled alcohol.

Meanwhile, police officers were later seen at the NAFDAC Isolo premises, which dispersed the blockade to allow NAFDAC staff back into the premises.

Representatives of the Director-General of NAFDAC later engaged the protesting union in talks, but the meeting ended without resolution as demonstrators insisted their agitation would continue.

Union leaders presented their concerns during closed-door discussions with a director within the agency and the Special Assistant to the Director-General. However, no agreement was reached.

The protesters are urging NAFDAC to reconsider what they describe as the strict enforcement of the ban on sachet alcohol. Instead, they want the agency to focus on regulating access to such products, particularly by restricting sales to minors, while intensifying public enlightenment campaigns on responsible consumption.

Despite this, protesters say they will not stop until their demands are addressed.

Continue Reading

Trending